Trial Profile
Pharmacokinetic study of amrubicin in lung cancer patients with impaired hepatic function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Lung cancer; Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sumitomo Dainippon Pharma
- 12 Dec 2015 New trial record